FDA-approved CooperVision's MiSight 1 Day Contact Lenses are daily wear, single-use contacts that have been shown to slow the progression of myopia (nearsightedness) in children aged 8 to 12 years old at the start of treatment. Slowing the progression of myopia in children may reduce their risk of developing severe eye diseases such as macular degeneration, retinal detachment, and glaucoma later in life.
Myopia Management In a Nutshell
Myopia, which occurs in school-aged children, is not a static condition; by the time you bring your child to their next eye exam, their level of nearsightedness likely will have increased. It typically stabilizes by the age of 20.
According to the American Optometric Association, 34% of American children ages 12-17 are myopic. All the more worrying is that, by 2050, myopia is expected to affect at least 5 billion people globally. In some areas of Asia, the rates are already surpassing 80-90% by the time teens attend university.
This is due in part to changing lifestyles, with children spending less time outdoors and more time focusing on close objects like digital screens. The long-term risks associated with myopia progression pose a serious public health challenge, and the World Health Organization and other international health bodies and NGOs have already added myopia to the agenda of serious concerns.
The goal in myopia management is to reduce abnormal eye growth and elongation. Once a child is diagnosed with myopia, eye doctors typically prescribe eyeglasses or standard contact lenses. While these help the child see better, they cannot slow myopia’s progression. By using the most advanced myopia management methods — like MiSight contact lenses — our team of eye doctors can help your child slow the progression of myopia and limit the risks of vision-robbing eye diseases later in life.